1. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppressio n in vivo by a soluble form of the CTLA4 T cell activation molecule. Science, 1992; 257: 792
2. Janeway CA, Bottornley K. Signals and sig ns for lymphocyte responses. Cell, 1994;76: 275
3. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science, 1990;248: 1349
4. Gimmi CD, Freeman GJ, Gribben JG, et al. Human T cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA, 1993; 90:6580
5. Nael PJ, Boise LH, Green JM, et al. CD28 costimulation presents cell death during primary T cell activation. J Immunol, 1996;157:636
6. Wu Y, Guo Y, Liu Y, et al. A major costimulatory molecule on antigen-pressenting cells, CTLA4 ligand A, is distinct from B7.J Exp Med, 1993;178: 1789
7. Hathcock K S, Laszlo G, Dickler HB, et al. Indentification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science, 1993; 262: 905
8. Linsley PS, Brandy W, Urnes M, et al. Second receptor for B cells activation antigen B7.J Exp Med, 1991; 174: 561
9. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med, 1991;173:721
10. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA, 1992;89: 11102
11. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Longterm survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science, 1992;257: 789
12. Bierer BE, Hollander G, Fruman D, et al. Cyclosporin A and FK506: molecular mechanism of immunosuppression and probes for transplantation biology. Curr Opin Immunol, 1993;5: 763
13. Feng S, Quickel RR, Hollister-Lock J, et al. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig. Transplantation, 1999; 67: 1607
14. Yang Z, Rostami S, Koebeilein B, et al. Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig. Transplantation, 1999; 67: 1517
15. Gebbarbt BM, Hodkin M, Varnell ED, et al. Protection of corneconal allografts by CT LA4-Ig. Cornea, 1999;18: 314
16. Pearson TC, Alexander DZ, Winn kJ, et al. Transplantation tolerance induced by CTLA4Ig. Transplantation, 1994; 57: 1701
17. Azuma H, Chandraker A, Nadeau K, et al. Blockade of T-cell costimlation prevents development of experimental chronic renal allograft rejection. Proc Natl Sci USA, 1996;93: 12439
18. Quattrocchi E, Dallman MJ, Feldmann M. Adenovirusmediated gene transfer of CTLA4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum, 2000;43: 1688
19. Via CS, Rus V, Nguyen P, et al. Differential effect of CT LA4I g on murine graft-versus-host disease (GVHD) development: CTLA4I g prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol, 1996; 157:4258
20. Sato J, Asakura K, Murakami M, et al. Suppressive effects of CYLA4Ig on nasal allergic reactions in presensitized murine model. Life Sci, 1999;64: 785
21. Padrid PA, Mathur M, Li X, et al. CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/ Th2 subsets in a murine model of asthma. AM J Respir Cell Mol Biol, 1998; 18: 453
22. Weiner RS, Srinivas NR, Calo re JD, et al. A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection. J Pharm Biomed Anal, 1997;15: 571
23. Srinivas NR, Shyu WC, Weiner RS, et al. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. J Pharm Res, 1997; 14: 911
24. Srinivas NR, Weiner RS, Shyu WC, et al. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. J Pharm Sci, 1996; 85:296
25. Srinivas NR, Shy u WC, Weiner RS, et al. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive e agent, following intravenous and subcutaneous administration to mice. J Pharm Sci, 1995; 84: 1488
26. Srinivas NR, Weiner RS, Warner G, et al. Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuoppressive agent, in monkeys following multiple doses. J Pharm Sci, 1996; 85: 17 |
